{"product_id":"seracare-seraseq-compromised-ffpe-tumor-dna-reference-material-0710-1492","title":"Seraseq® Compromised FFPE Tumor DNA Reference Material","description":"\u003cp\u003eComprehensive genomic profiling (CGP) is an important part of an integrated clinical management of cancer patients, where cancer patients harboring variants\/biomarkers of clinical utility are determined by highly multiplexed targeted NGS assay testing. Precise analysis of these patient samples requires high quality sample-to-result assay workflow controls to guide and validate the accurate identification of these actionable variants.\u003c\/p\u003e\u003cp\u003eLGC SeraCare has developed a highly multiplexed Compromised FFPE Tumor DNA reference material imbibing “patient-like” characteristics to support end-to-end NGS workflows performed by clinical labs in the analysis of cancer patient samples. This product consists of 17 genes and 34 variants, incorporating all variant types – SNVs, INDELs, CNVs, and SVs. These variants were precisely quantitated by digital PCR and targeted NGS against a single well-characterized genomic background (GM24385).\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eHighly multiplexed FFPE Tumor DNA reference material\u003c\/li\u003e\n\u003cli\u003eContains 34 variants in 17 genes\u003c\/li\u003e\n\u003cli\u003eAll variant types – SNVs (18), INDELs (10), CNVs (3) and SVs (3)\u003c\/li\u003e\n\u003cli\u003eFor use in sample-to-result NGS workflows to analyze for mutation-positive variants in patient samples\u003c\/li\u003e\n\u003cli\u003eManufactured in GMP-compliant ISO 13485 certified facility\u003c\/li\u003e\n\u003c\/ul\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\u003ctd colspan=\"4\"\u003e\u003cstrong\u003eGene List\u003c\/strong\u003e\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eATK1\u003c\/td\u003e\n\u003ctd\u003eEGFR\u003c\/td\u003e\n\u003ctd\u003eMYC\u003c\/td\u003e\n\u003ctd\u003eCD74-ROSI\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eALK\u003c\/td\u003e\n\u003ctd\u003eERBB2\u003c\/td\u003e\n\u003ctd\u003eNRAS\u003c\/td\u003e\n\u003ctd\u003eNCOA4-RET\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBRAF\u003c\/td\u003e\n\u003ctd\u003eKIT\u003c\/td\u003e\n\u003ctd\u003ePIK3CA\u003c\/td\u003e\n\u003ctd\u003eEML4-ALK\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBRCA1\u003c\/td\u003e\n\u003ctd\u003eKRAS\u003c\/td\u003e\n\u003ctd\u003eTP53\u003c\/td\u003e\n\u003ctd\u003e \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBRCA2\u003c\/td\u003e\n\u003ctd\u003eMET\u003c\/td\u003e\n\u003ctd\u003e \u003c\/td\u003e\n\u003ctd\u003e \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eSpecifications\u003c\/h2\u003e\u003ctable\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e# of genes\u003c\/td\u003e\n\u003ctd\u003e17\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSize\u003c\/td\u003e\n\u003ctd\u003e10 µm\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormat\u003c\/td\u003e\n\u003ctd\u003eFFPE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDNA Yield\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100 ng*\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\u003ch2\u003eDocuments\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/pi-0710-1492-seraseq-compromised-ffpe-tumor-dna-rm.pdf\" target=\"_blank\" rel=\"noopener\"\u003ePackage Insert for Seraseq® Compromised FFPE Tumor DNA RM (Package Insert)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/tss-0710-1492-seraseq-compromised-ffpe-tumor-dna-rm.xlsx\" target=\"_blank\" rel=\"noopener\"\u003eTechnical Spreadsheet for Seraseq Compromised FFPE Tumor DNA RM (Technical Spreadsheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.seracare.com\/globalassets\/seracare-resources\/sds-seraseq-ffpe.pdf\" target=\"_blank\" rel=\"noopener\"\u003eSeraseq FFPE Safety Data Sheet (Safety Data Sheet)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eOrdering Information\u003c\/h2\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCat. no.\u003c\/th\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003e0710-1492\u003c\/td\u003e\n\u003ctd\u003eSeraseq® Compromised FFPE Tumor DNA RM\u003c\/td\u003e\n\u003ctd\u003e1 x 10 µm\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"SeraCare","offers":[{"title":"Default Title","offer_id":46798511145039,"sku":"0710-1492","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/0710-1492.jpg?v=1789655833","url":"https:\/\/www.danyel.co.il\/products\/seracare-seraseq-compromised-ffpe-tumor-dna-reference-material-0710-1492","provider":"danyel biotech","version":"1.0","type":"link"}